tadalafil has been researched along with 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid in 1 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid) | Trials (15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid) | Recent Studies (post-2010) (15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 2,577 | 27 | 327 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chikazawa, S; Hori, Y; Hoshi, F; Itoh, N; Kanai, K; Kondo, C; Matsui, M; Okano, S; Yamagishi, M | 1 |
1 trial(s) available for tadalafil and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
| Article | Year |
|---|---|
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Intravenous; Administration, Oral; Animals; Carbolines; Cross-Over Studies; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Hemodynamics; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Random Allocation; Tadalafil; Time Factors; Vascular Resistance; Vasoconstrictor Agents | 2014 |